GHIT Fund sponsors malaria vaccine development at CMP

The Global Health Innovative Technology (GHIT) Fund has decided to sponsor a malaria vaccine development project led by the European Vaccine Initiative, the Research Institute for Microbial Diseases (RIMD) at Osaka University, the University of Copenhagen, the University of Tübingen, Danish biotechnology company AdaptVac, Ajinomoto Co., Inc., and Nobelpharma Co., Ltd.

Morten Nielsen (BIVAC team) is the CMP representative in this collaboration. 

Topics